

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EDDING GENOR GROUP HOLDINGS LIMITED

亿腾嘉和醫藥集團有限公司

(formerly known as Genor Biopharma Holdings Limited
嘉和生物藥業(開曼)控股有限公司)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

VOLUNTARY ANNOUNCEMENT LATEST UPDATE ON COOPERATION WITH CANDID THERAPEUTICS

This announcement is made by Edding Genor Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Group about the latest business advancement of the Group. References are made to the announcements of the Company dated 5 August 2024 and 30 June 2025 in relation to the progress of GB261.

On 2 August 2024, the Group has entered into a license agreement (the “**License Agreement**”) and a stock purchase agreement (the “**Stock Purchase Agreement**”) with TRC 2004, Inc. (the “**Licensee**”). Pursuant to the License Agreement, the Group has agreed, among others, to grant the Licensee an exclusive worldwide license to develop, use, manufacture, commercialize and otherwise exploit GB261, excluding mainland China, Hong Kong, Macau and Taiwan. Within the terms of the License Agreement and Stock Purchase Agreement, in consideration of the license, the Group shall receive (i) equity participation in the Licensee; (ii) a double digit million US dollars upfront payment; (iii) up to 443 million US dollars in milestone payments; and (iv) tiered single to double digits royalty payments on net sales. In September 2024, Candid Therapeutics, Inc. merged with TRC 2004, Inc. In connection with the said merger, TRC 2004, Inc. assigned its rights under the License Agreement to Candid Therapeutics, Inc. (“**Candid Therapeutics**”) in December 2024, and the Group’s equity interest in TRC 2004, Inc. previously acquired pursuant to the Stock Purchase Agreement, was converted into equity interest in Candid Therapeutics. The Group and Candid Therapeutics entered into an amendment agreement dated 28 March 2025 to amend and supplement certain terms of the License Agreement to jointly advance the clinical development of GB261 in autoimmune diseases. Multiple clinical studies, including those in rheumatoid arthritis and systemic lupus erythematosus, have been initiated, continuously expanding its therapeutic applications.

On 3 May 2026, Union Chimique Belge (“**UCB**”), a Belgian pharmaceutical group listed on Euronext Brussels (ticker symbol: UCB), announced the execution of a definitive agreement under which it would acquire Candid Therapeutics. Under the terms of the agreement, UCB shall make an upfront payment of US\$2 billion, together with potential future milestone payments of up to US\$200 million, contingent upon the achievement of specified milestones. The acquisition remains subject to certain closing conditions, including required anti-trust clearance and other customary conditions, and is expected to close by the end of the second quarter to early third quarter of 2026.

ABOUT GB261

GB261 is a differentiated bispecific antibody targeting CD3 and CD20 for the treatment of B-cell lymphoma and autoimmune diseases. The molecule incorporates a unique low-affinity CD3 design, effectively reducing cytokine release-related safety risks and providing advantages in clinical development. Currently, a Phase I/II dose escalation study has been completed, demonstrating an excellent safety profile and a favourable balance between efficacy and safety in patients with DLBCL and FL.

By Order of the Board
Edding Genor Group Holdings Limited
Mr. Ni Xin
Chairman and Executive Director

Hong Kong, 4 May 2026

As of the date of this announcement, the Board comprises Mr. Ni Xin and Dr. Han Shuhua as executive Directors; Dr. David Guowei Wang and Mr. Yu Tieming as non-executive Directors; and Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing as independent non-executive Directors.